Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss their approach to biomarker testing in advanced endometrial cancer, including the timing and types of testing performed, the specific biomarkers assessed (such as mismatch repair/microsatellite instability, POLE, and TP53), and how these results inform treatment decisions.

EP: 1.Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 2.Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP: 3.Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP: 4.Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP: 5.Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP: 6.Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP: 7.Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP: 8.Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP: 9.Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

Now Viewing

EP: 10.Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

Video content above is prompted by the following:

How do you typically approach biomarker testing for advanced endometrial cancer?

When do you test/retest, and what type of testing do you perform?
Which biomarkers do you generally access (eg, mismatch repair/microsatellite instability, POLE, TP53, etc) and how do results help guide your treatment approach?